BioSpace News Archive

Ascentage Pharma announced that the company has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, part of National Institutes of Health, under which they will collaborate on the non-clinical and clinical development of Ascentage Pharma’s drug compound pelcitoclax.

The presentation identifies a statistically significant effect of ZYESAMI™ in preventing the sharp rise in cytokines, commonly associated with mortality in patients with COVID-19.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial results prior to market open on Thursday, July 29, 2021.

Eluminex Biosciences Limited announced that it has exclusively licensed global rights for the development and commercialization of an investigational biosynthetic cornea derived from recombinant human collagen Type III intended to treat patients with corneal blindness, from FibroGen, Inc..

Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced the appointment of Martin Babler to its Board of Directors.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced that it will present clinical electroencephalogram data, including in Alzheimer’s patients, from the Phase 1 a/b trial of its lead development candidate, ATH-1017, at the upcoming Alzheimer’s Association International Conference 2021.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, announced three key leadership appointments.

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib [1] in patients hospitalized with severe COVID-19 pneumonia.

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that the first patient has been dosed in the cohort expansion arm of the Phase 1/2 study evaluating the triple combination of COM701, Compugen’s first-in-class anti-PVRIG antibody, with Opdivo® and Bristol Myers Squibb’s investigational anti-TIGIT antibody, BMS-986207.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced that it has converted all of the $28.0 million aggregate principal of the Company’s 2020 5.00% Convertible Senior Notes due 2048 in exchange for approximately 8.6 million shares of the Company’s common stock, based on the Company’s existing Mandatory Conversion right.